XML 261 R215.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segment information - Schedule of Segment Results (Details)
€ in Millions
 12 Months Ended
Dec. 31, 2023
EUR (€)
segment
Dec. 31, 2022
EUR (€)
segment
Dec. 31, 2021
EUR (€)
Disclosure of operating segments [line items]      
Net sales € 43,070 € 42,997 € 37,761
Other revenues 3,374 2,392 1,414
Cost of sales (14,236) (13,695) (12,255)
Research and development expenses (6,728) (6,706) (5,692)
Selling and general expenses (10,692) (10,492) (9,555)
Share of profit/(loss) from investments accounted for using the equity method (115) 68 39
Net income attributable to non-controlling interests € 36 € 113 56
Number of operating segments | segment 2 3  
Total Sanofi      
Disclosure of operating segments [line items]      
Net sales € 43,070 € 42,997 37,761
Other revenues 3,374 2,392 1,414
Cost of sales (14,216) (13,692) (12,251)
Research and development expenses (6,728) (6,706) (5,692)
Selling and general expenses (10,692) (10,492) (9,555)
Other operating income and expenses (2,224) (1,514) (946)
Share of profit/(loss) from investments accounted for using the equity method 122 88 39
Net income attributable to non-controlling interests (36) (33) (56)
Business operating income 12,670 13,040 10,714
Biopharma      
Disclosure of operating segments [line items]      
Net sales 37,890 37,812 33,293
Other revenues 3,322 2,330  
Cost of sales (12,282) (11,793)  
Research and development expenses (6,509) (6,503)  
Selling and general expenses (8,868) (8,736)  
Other operating income and expenses (2,387) (1,679)  
Share of profit/(loss) from investments accounted for using the equity method 101 76  
Net income attributable to non-controlling interests (20) (17)  
Business operating income 11,247 11,490  
Pharmaceuticals      
Disclosure of operating segments [line items]      
Net sales     26,970
Other revenues     264
Cost of sales     (6,965)
Research and development expenses     (4,330)
Selling and general expenses     (5,326)
Other operating income and expenses     (1,172)
Share of profit/(loss) from investments accounted for using the equity method     17
Net income attributable to non-controlling interests     (49)
Business operating income     9,409
Vaccines      
Disclosure of operating segments [line items]      
Net sales     6,323
Other revenues     1,095
Cost of sales     (3,430)
Research and development expenses     (712)
Selling and general expenses     (805)
Other operating income and expenses     128
Share of profit/(loss) from investments accounted for using the equity method     11
Net income attributable to non-controlling interests     (1)
Business operating income     2,609
Consumer Healthcare      
Disclosure of operating segments [line items]      
Net sales 5,180 5,185 4,468
Other revenues 52 62 55
Cost of sales (1,933) (1,903) (1,606)
Research and development expenses (219) (205) (153)
Selling and general expenses (1,828) (1,761) (1,388)
Other operating income and expenses 181 148 111
Share of profit/(loss) from investments accounted for using the equity method 21 12 11
Net income attributable to non-controlling interests (16) (16) (5)
Business operating income 1,438 1,522 1,493
Other      
Disclosure of operating segments [line items]      
Net sales 0 0 0
Other revenues 0 0 0
Cost of sales (1) 4 (250)
Research and development expenses 0 2 (497)
Selling and general expenses 4 5 (2,036)
Other operating income and expenses (18) 17 (13)
Share of profit/(loss) from investments accounted for using the equity method 0 0 0
Net income attributable to non-controlling interests 0 0 (1)
Business operating income € (15) € 28 € (2,797)